Who are Colesevelam Cholestagel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Welchol, Colestid, Questran Light, colesevelam HCl, "cholestagel®" (Colesevelam), Cholestyramine Powder.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/colesevelam-cholestagel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Colesevelam Cholestagel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Colesevelam Cholestagel (Colesevelam Cholestagel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile acid sequestrant. Area: Cardiovascular, Endocrinology.

phase 2 Bile acid sequestrant Bile acids (non-selective binding) Cardiovascular, Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Colesevelam Cholestagel (Colesevelam Cholestagel) — Genzyme, a Sanofi Company. Colesevelam is a bile acid sequestrant that binds bile acids in the intestine to prevent their reabsorption, thereby lowering LDL cholesterol and improving glycemic control.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Colesevelam Cholestagel TARGET	Colesevelam Cholestagel	Genzyme, a Sanofi Company	phase 2	Bile acid sequestrant	Bile acids (non-selective binding)
Welchol	COLESEVELAM	Cosette	marketed	Bile Acid Sequestrant		2000-01-01
Colestid	Colestipol	Pfizer	marketed	Bile Acid Sequestrant		1977-01-01
Questran Light	CHOLESTYRAMINE	Bristol Myers	marketed	Bile Acid Sequestrant [EPC]		1973-01-01
colesevelam HCl	colesevelam HCl	HealthPartners Institute	marketed	Bile acid sequestrant	Bile acids
"cholestagel®" (Colesevelam)	"cholestagel®" (Colesevelam)	University Hospital, Gentofte, Copenhagen	marketed	Bile acid sequestrant	Bile acids
Cholestyramine Powder	Cholestyramine Powder	Centre Hospitalier Universitaire de Nice	marketed	Bile acid sequestrant	Bile acids

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bile acid sequestrant class)

Albireo · 1 drug in this class
Centre Hospitalier Universitaire de Nice · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
HealthPartners Institute · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Taejoon Pharmaceutical Co., Ltd. · 1 drug in this class
University Hospital, Gentofte, Copenhagen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Colesevelam Cholestagel — Competitive Intelligence Brief. https://druglandscape.com/ci/colesevelam-cholestagel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab